[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Generic_Tina Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1511682976639119365.png) @Generic_Tina Tina Banerjee

Tina Banerjee posts on X about future, core, china, strong the most. They currently have XX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1511682976639119365/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:interactions.svg)

- X Week XXX -XX%
- X Month XXXXX -XX%
- X Months XXXXX +88%
- X Year XXXXXX +272%

### Mentions: X [#](/creator/twitter::1511682976639119365/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX -XX%
- X Months XXX +48%
- X Year XXX +226%

### Followers: XX [#](/creator/twitter::1511682976639119365/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:followers.svg)

- X Week XX no change
- X Month XX -XXXX%
- X Months XX +33%
- X Year XX +46%

### CreatorRank: undefined [#](/creator/twitter::1511682976639119365/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  XXXXX% [countries](/list/countries)  XXXXX% [technology brands](/list/technology-brands)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[future](/topic/future) 15.79%, [core](/topic/core) 10.53%, [china](/topic/china) 10.53%, [strong](/topic/strong) 10.53%, [business](/topic/business) 10.53%, [$100m](/topic/$100m) 5.26%, [$325m](/topic/$325m) 5.26%, [$420450m](/topic/$420450m) 5.26%, [$4523t](/topic/$4523t) 5.26%, [turnaround](/topic/turnaround) XXXX%
### Top Social Posts
Top posts by engagements in the last XX hours

"Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth"  
[X Link](https://x.com/Generic_Tina/status/1973547314955587688)  2025-10-02T00:35Z XX followers, XX engagements


"in 3Q25 SKBP reported U.S. sales of Xcopri exceeding $100M for the second time. During 9M25 U.S. sales of Xcopri reached $325M with full-year 2025 guidance remaining at $420450M"  
[X Link](https://x.com/Generic_Tina/status/1993478610905342352)  2025-11-26T00:35Z XX followers, XX engagements


"Takeda and Eisai witnessed clinical trials setback. Wuxi AppTec is selling China-based CRO subsidiaries. CSL is delaying demerger of CSL Seqirus. PharmaEssentia filed label expansion of Besremi in US"  
[X Link](https://x.com/Generic_Tina/status/1984781327884050659)  2025-11-02T00:35Z XX followers, XXX engagements


"SK Bioscience sees 2.5x revenue growth and reduced operating loss in 3Q25 driven by strong performance of IDT Biologika. Strong base business and IDT turnaround will drive near-term growth"  
[X Link](https://x.com/Generic_Tina/status/1985868489253609912)  2025-11-05T00:35Z XX followers, XX engagements


"Celltrion inlicensed twoantibodydrug candidates in KRW1T deal. Dong-A got domestic approval for Xcopri. Hanmi Pharm will distribute Boehringer Ingelheims three major COPD treatments"  
[X Link](https://x.com/Generic_Tina/status/1987318035854893563)  2025-11-09T00:35Z XX followers, XX engagements


"3SBio will spin-off and separately list its subsidiary. Celltrion got EC approval for Remsima IV liquid. Hanmi Pharm is acquiring Aptose Biosciences. CHMP recommends approval of Otsukas donidalorsen"  
[X Link](https://x.com/Generic_Tina/status/1992391459623092713)  2025-11-23T00:35Z XX followers, XX engagements


"Innovent Biologics reports 1H25 results with XX% revenue growth and maiden net profit driven by core oncology product Tyvyt. Mazdutide approval in China along witth Tyvyt to drive future growth"  
[X Link](https://x.com/Generic_Tina/status/1992968672974148080)  2025-11-24T14:48Z XX followers, XX engagements


"3SBio Inc announces placement of 105.2M shares at HK$29.62/share for R&D and working capital. Placement attractive given 3SBio's pipeline potential and indirect access to spun off Mandi shares"  
[X Link](https://x.com/Generic_Tina/status/1996015348039254250)  2025-12-03T00:35Z XX followers, XX engagements


"Simcere stuck license pact with Vigonvita. Kelun Bio inked partnership with Crescent Biopharma. Samsung Biologics is acquiring land for third campus. Biocon settled with Amgen for Prolia biosimilar"  
[X Link](https://x.com/Generic_Tina/status/1997464896636932332)  2025-12-07T00:35Z XX followers, XX engagements


"Nippon Shinyaku and Capricor announce positive Phase X results for Deramiocel with potential FDA approval and commercialization on the horizon. Near term concerns with Viltepso remain"  
[X Link](https://x.com/Generic_Tina/status/1997827292417163681)  2025-12-08T00:35Z XX followers, XX engagements


"Santen Pharma sees revenue and profits decline in H1FY26. Expects strong H2FY26 with growth in EMEA and Asia driving overseas business rise. Drug development and market leadership future accretive"  
[X Link](https://x.com/Generic_Tina/status/1998914435990302937)  2025-12-11T00:35Z XX followers, XX engagements